An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

A recent award ceremony which is actually significant revealed about the best companies right now existing in the country US ...

The global diabetic nephropathy market was valued at $1.9 billion in 2021, and is projected to reach $3.3 billion by 2031, growing at a CAGR of 6%.

Global Capability Centers — offshore units that handle the parent’s business processes — accounted for over a third of the ...

StockNews.com upgraded shares of Xerox (NYSE:XRX – Free Report) from a hold rating to a buy rating in a report issued on Tuesday morning. Several other research analysts also recently commented on XRX ...

But some political forces—and Ghanaians, in fact—choose to dismiss this as an Oliver asking for more, Yet, this does not take ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...